
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is a promising biopharmaceutical company with a diversified product portfolio, including BRUKINSA and sonrotoclax, targeting multiple mechanisms of action in oncology. The company's recent Q1 results show strong revenue growth and a beat in revenue and earnings estimates, leading to an increased FY26 guidance. Upcoming catalysts such as the potential approval of sonrotoclax and updates on solid tumor programs, including the GPC3 x 4-1BB bsAb, could contribute significantly to future revenues. However, there are risks related to R&D, regulatory, and commercial setbacks that could affect the company's success. Overall, the company's strong position in the CLL market and potential for long-term value creation make it a buy.
Bears say
BeOne Medicines is currently operating at a loss due to their numerous ongoing trials and relatively high research and development expenses, with a potential filing for BTK-CDAC in 2H26 and initial data for several other programs not expected until 2026. Additionally, the company has deprioritized several early-stage programs based on early data, and while their BTK-CDAC could potentially generate significant revenue in the near-term, it may not be enough to offset their current losses. As a result, financial analysts have a negative outlook on BeOne Medicines' stock.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares